ERBB2 and breast cancer: Arvold et al. [37] approximated these subtypes based on immunohistochemistry and grade and determined the 5-year cumulative incidence of local recurrence was 0.8% for Luminal A, 2.3% for Luminal B, 1.1% for Luminal HER-2, 10.8% for HER2-enriched and 6.7% for Basal-like early stage breast cancers.